Tenpoint Therapeutics has raised £54 million Series A funding to develop breakthrough regenerative treatments for eye diseases.
The company is based on the work of its scientific founders from Moorfields Eye Hospital, the UCL Institute of Ophthalmology, Institut de la Vision and the University of Washington.
It is developing a series of ex vivo and in vivo cell engineering approaches which will provide long-term treatment options for restoration of vision by replacing lost and dysfunctional tissue in the eye.
Tenpoint aims to deliver therapies that could deliver benefits to patients affected by a large number of degenerative eye diseases.
British Patient Capital invested £10m, its ninth investment in the life sciences sector via Future Fund: Breakthrough, a £375m programme where it co-invests with private sector investors in innovative, R&D-intensive UK companies.
It joins investors Sofinnova Partners, F-Prime Capital, UCL Technology Fund, Eight Roads and Qiming.
https://businesscloud.co.uk/medtech-50-uks-most-innovative-medical-technology-creators/
“Cell engineering and gene therapy are key frontiers in life sciences today,” Catherine Lewis La Torre, CEO of British Patient Capital. “In order for us to remain at the forefront, it is vital that we back the right technologies and invest in the most innovative companies in this sector with the potential to scale.
“Tenpoint Therapeutics has been built on the pioneering work of its scientific founders who are recognised leaders in ocular therapies. Their vision combined with research excellence provides the best foundation to develop treatments that could be game-changers for millions of patients worldwide.”
Eddy Anglade, MD and CEO of Tenpoint, said: “Cell-based therapeutics represent an ideal modality for degenerative ocular diseases since most vision loss results from damaged or missing tissue. In recent years, a number of new technological advancements have converged to make this modality both clinically viable and scalable.
“At Tenpoint, we are focused exclusively on the eye and on harnessing recent advances in regenerative biology to advance our therapies as we work to change the future for people with vision loss by addressing its underlying causes.”